

Hepatocellular Carcinoma - Pipeline Review, H1 2018

<https://marketpublishers.com/r/H291334421BEN.html>

Date: May 2018

Pages: 1275

Price: US\$ 2,500.00 (Single User License)

ID: H291334421BEN

Abstracts

Hepatocellular Carcinoma - Pipeline Review, H1 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatocellular Carcinoma - Pipeline Review, H1 2018, provides an overview of the Hepatocellular Carcinoma (Oncology) pipeline landscape.

Hepatocellular carcinoma (HCC) is a type of cancer originates from a liver cell (hepatocyte) which becomes cancerous. This type of cancer occurs more often in men than women. Symptoms include abdominal pain or tenderness, especially in the upper-right part, easy bruising or bleeding, enlarged abdomen and yellow skin or eyes (jaundice). The predisposing factors include alcohol abuse, autoimmune diseases of the liver, hepatitis B or C virus infection, inflammation of the liver that is long-term (chronic) and iron overload in the body (hemochromatosis). Treatment includes surgery, chemotherapy and radiation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatocellular Carcinoma - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hepatocellular Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatocellular Carcinoma (Oncology) pipeline guide also reviews of key players

involved in therapeutic development for Hepatocellular Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 18, 76, 60, 1, 3, 92, 13 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 10, 6, 1, 1, 25 and 1 molecules, respectively.

Hepatocellular Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatocellular Carcinoma (Oncology).

The pipeline guide reviews pipeline therapeutics for Hepatocellular Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hepatocellular Carcinoma

(Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hepatocellular Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hepatocellular Carcinoma (Oncology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hepatocellular Carcinoma (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hepatocellular Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Hepatocellular Carcinoma - Overview

Hepatocellular Carcinoma - Therapeutics Development

Hepatocellular Carcinoma - Therapeutics Assessment

Hepatocellular Carcinoma - Companies Involved in Therapeutics Development

Hepatocellular Carcinoma - Drug Profiles

Hepatocellular Carcinoma - Dormant Projects 1218

Hepatocellular Carcinoma - Discontinued Products 1227

Hepatocellular Carcinoma - Product Development Milestones 1230

Appendix 1244

List Of Tables

LIST OF TABLES

Number of Products under Development for Hepatocellular Carcinoma, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Hepatocellular Carcinoma - Pipeline by AbbVie Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by Abivax SA, H1 2018
Hepatocellular Carcinoma - Pipeline by ACEA Biosciences Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by Adaptimmune Therapeutics Plc, H1 2018
Hepatocellular Carcinoma - Pipeline by Advenchen Laboratories LLC, H1 2018
Hepatocellular Carcinoma - Pipeline by Alnylam Pharmaceuticals Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by American Gene Technologies International Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by Amgen Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by AndroScience Corp, H1 2018
Hepatocellular Carcinoma - Pipeline by ArQule Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by Array BioPharma Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2018
Hepatocellular Carcinoma - Pipeline by AstraZeneca Plc, H1 2018
Hepatocellular Carcinoma - Pipeline by AVEO Pharmaceuticals Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by Bavarian Nordic A/S, H1 2018
Hepatocellular Carcinoma - Pipeline by Bayer AG, H1 2018
Hepatocellular Carcinoma - Pipeline by BeiGene Ltd, H1 2018
Hepatocellular Carcinoma - Pipeline by Bio-Cancer Treatment International Ltd, H1 2018
Hepatocellular Carcinoma - Pipeline by Biomics Biotechnologies Co Ltd, H1 2018
Hepatocellular Carcinoma - Pipeline by Bioneer Corp, H1 2018
Hepatocellular Carcinoma - Pipeline by Blueprint Medicines Corp, H1 2018
Hepatocellular Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H1 2018
Hepatocellular Carcinoma - Pipeline by Boston Biomedical Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by Bristol-Myers Squibb Co, H1 2018

Hepatocellular Carcinoma - Pipeline by Can-Fite BioPharma Ltd, H1 2018
Hepatocellular Carcinoma - Pipeline by CARsgen Therapeutics Ltd, H1 2018
Hepatocellular Carcinoma - Pipeline by CASI Pharmaceuticals Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by CBT Pharmaceuticals Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by CCRP Therapeutics GmbH, H1 2018
Hepatocellular Carcinoma - Pipeline by Celgene Corp, H1 2018
Hepatocellular Carcinoma - Pipeline by Cellular Biomedicine Group Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by Celsion Corp, H1 2018
Hepatocellular Carcinoma - Pipeline by China Medical System Holdings Ltd, H1 2018
Hepatocellular Carcinoma - Pipeline by Chipscreen Biosciences Ltd, H1 2018
Hepatocellular Carcinoma - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018
Hepatocellular Carcinoma - Pipeline by Conatus Pharmaceuticals Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by Curevac AG, H1 2018
Hepatocellular Carcinoma - Pipeline by Delcath Systems Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by Double Bond Pharmaceutical International AB, H1 2018
Hepatocellular Carcinoma - Pipeline by eFFECTOR Therapeutics Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by Eiger BioPharmaceuticals Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by Eisai Co Ltd, H1 2018
Hepatocellular Carcinoma - Pipeline by Eli Lilly and Co, H1 2018
Hepatocellular Carcinoma - Pipeline by Epeius Biotechnologies Corp, H1 2018
Hepatocellular Carcinoma - Pipeline by Epizyme Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by Eureka Therapeutics Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by Exelixis Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Hepatocellular Carcinoma - Pipeline by Faron Pharmaceuticals Oy, H1 2018
Hepatocellular Carcinoma - Pipeline by Galaxy Biotech LLC, H1 2018
Hepatocellular Carcinoma - Pipeline by GC Pharma, H1 2018
Hepatocellular Carcinoma - Pipeline by Genelux Corp, H1 2018
Hepatocellular Carcinoma - Pipeline by Genentech Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by Genoscience Pharma, H1 2018
Hepatocellular Carcinoma - Pipeline by Genosco Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by Gilead Sciences Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by GlaxoSmithKline Plc, H1 2018
Hepatocellular Carcinoma - Pipeline by Golden Biotechnology Corp, H1 2018
Hepatocellular Carcinoma - Pipeline by H3 Biomedicine Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018
Hepatocellular Carcinoma - Pipeline by Horizon Pharma Plc, H1 2018
Hepatocellular Carcinoma - Pipeline by Immatics Biotechnologies GmbH, H1 2018

Hepatocellular Carcinoma - Pipeline by Immunicum AB, H1 2018

Hepatocellular Carcinoma - Pipeline by Immunitor Inc, H1 2018

Hepatocellular Carcinoma - Pipeline by Immunomedics Inc, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development for Hepatocellular Carcinoma, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Top 10 Routes of Administration, H1 2018
Number of Products by Stage and Top 10 Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018

COMPANIES MENTIONED

AbbVie Inc
Abivax SA
ACEA Biosciences Inc
Adaptimmune Therapeutics Plc
Advenchen Laboratories LLC
Alynlam Pharmaceuticals Inc
American Gene Technologies International Inc
Amgen Inc
AndroScience Corp
ArQule Inc
Array BioPharma Inc
Aslan Pharmaceuticals Pte Ltd
AstraZeneca Plc
AVEO Pharmaceuticals Inc
Bavarian Nordic A/S
Bayer AG
BeiGene Ltd
Bio-Cancer Treatment International Ltd
Biomics Biotechnologies Co Ltd
Bioneer Corp
Blueprint Medicines Corp

Boehringer Ingelheim GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Co
Can-Fite BioPharma Ltd
CARsgen Therapeutics Ltd
CASI Pharmaceuticals Inc
CBT Pharmaceuticals Inc
CCRP Therapeutics GmbH
Celgene Corp
Cellular Biomedicine Group Inc
Celsion Corp
China Medical System Holdings Ltd
Chipscreen Biosciences Ltd
Chugai Pharmaceutical Co Ltd
Conatus Pharmaceuticals Inc
Curevac AG
Delcath Systems Inc
Double Bond Pharmaceutical International AB
eFFECTOR Therapeutics Inc
Eiger BioPharmaceuticals Inc
Eisai Co Ltd
Eli Lilly and Co
Epeius Biotechnologies Corp
Epizyme Inc
Eureka Therapeutics Inc
Exelixis Inc
F. Hoffmann-La Roche Ltd
Faron Pharmaceuticals Oy
Galaxy Biotech LLC
GC Pharma
Genelux Corp
Genentech Inc
Genoscience Pharma
Genosco Inc
Gilead Sciences Inc
GlaxoSmithKline Plc
Golden Biotechnology Corp
H3 Biomedicine Inc
Hanmi Pharmaceuticals Co Ltd

Horizon Pharma Plc
Immatics Biotechnologies GmbH
Immunicum AB
Immunitor Inc
Immunomedics Inc
Immunovative Therapies Ltd
In-Cell-Art SAS
Incyte Corp
Inovio Pharmaceuticals Inc
Inspyr Therapeutics Inc
InteRNA Technologies BV
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
KAHR medical Ltd
Karcinolys SAS
Kite Pharma Inc
Komipharm International Co Ltd
Kowa Co Ltd
Kura Oncology Inc
Leap Therapeutics Inc
Lixte Biotechnology Holdings Inc
MaxCyte Inc
MedImmune LLC
Medivir AB
MELEMA Pharma GmbH
Merck & Co Inc
Merck KGaA
Merrimack Pharmaceuticals Inc
Midatech Pharma Plc
Millennium Pharmaceuticals Inc
Mina Therapeutics Ltd
Molecular Templates Inc
MTG Biotherapeutics Inc
MultiCell Technologies Inc
NeuroVive Pharmaceutical AB
Nkarta Inc
NormOxys Inc
Novartis AG
NovaTarg Therapeutics Inc

Nymox Pharmaceutical Corp
Omeros Corp
Oncolys BioPharma Inc
Oncolytics Biotech Inc
Oneness Biotech Co Ltd
Ono Pharmaceutical Co Ltd
Oxford BioTherapeutics Ltd
PepVax Inc
Pfizer Inc
Pharma Mar SA
PharmAbcine Inc
PharmaEssentia Corp
Phosplatin Therapeutics LLC
Provecs Medical GmbH
Provectus Biopharmaceuticals Inc
Q BioMed Inc
RedHill Biopharma Ltd
Regulus Therapeutics Inc
Rexahn Pharmaceuticals Inc
Samumed LLC
Saronic Biotechnology Inc
Sensei Biotherapeutics Inc
Shanghai Henlius Biotech Co Ltd
Shenogen Pharma Group Ltd
Sillajen Biotherapeutics
Simcere Pharmaceutical Group
Spring Bank Pharmaceuticals Inc
Sun Pharma Advanced Research Company Ltd
Takeda Pharmaceutical Co Ltd
TC BioPharm Ltd
Tessa Therapeutics Pte Ltd
Therapure Biopharma Inc
Tiziana Life Sciences Plc
TRACON Pharmaceuticals Inc
Trovagene Inc
Tumorend LLC
Twoxar Inc
Tyrogenex Inc
VasGene Therapeutics Inc

Verlyx Pharma Inc
VG Life Sciences Inc
Vicus Therapeutics LLC
Xencor Inc
Xspray Pharma AB
Yooyoung Pharm Co Ltd
Zhejiang Conba Pharmaceutical Co Ltd

I would like to order

Product name: Hepatocellular Carcinoma - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/H291334421BEN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H291334421BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970